23andMe to Report FY2023 Second Quarter Financial Results
October 24 2022 - 4:05PM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human
genetics and biopharmaceutical company with a mission to help
people access, understand, and benefit from the human genome,
announced today that it will report financial results for the
fiscal year 2023 (FY2023) second quarter after the market closes on
Monday, November 7, 2022. The Company will webcast a conference
call at 4:30 p.m. Eastern Time on that date to discuss the
quarter’s financial results and report on business progress.
The webcast can be accessed on the day of the event at
https://investors.23andme.com/news-events/events-presentations. A
webcast replay will be available at the same address for a limited
time within 24 hours after the event.
In addition, 23andMe will use the Say
Technologies platform to allow retail and institutional
shareholders to submit and upvote questions to management in
advance of the earnings conference call. Starting today,
shareholders can submit questions by visiting
app.saytechnologies.com/23andme-2023-q2. The Q&A platform will
remain open until 24 business hours before the earnings call.
About 23andMe23andMe
is a genetics-led consumer healthcare and therapeutics company
empowering a healthier future. For more information, please visit
investors.23andme.com.
Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including statements regarding the future
performance of 23andMe’s businesses in consumer genetics and
therapeutics and the growth and potential of its proprietary
research platform. All statements, other than statements of
historical fact, included or incorporated in this press release,
including statements regarding 23andMe’s strategy, financial
position, funding for continued operations, cash reserves,
projected costs, plans, and objectives of management, are
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," "continue," "will,"
“schedule,” and "would" or, in each case, their negative or other
variations or comparable terminology, are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements are predictions based on 23andMe’s current expectations
and projections about future events and various assumptions.
23andMe cannot guarantee that it will actually achieve the plans,
intentions, or expectations disclosed in its forward-looking
statements and you should not place undue reliance on 23andMe’s
forward-looking statements. These forward-looking statements
involve a number of risks, uncertainties (many of which are beyond
the control of 23andMe), or other assumptions that may cause actual
results or performance to be materially different from those
expressed or implied by these forward-looking statements. The
forward-looking statements contained herein are also subject
generally to other risks and uncertainties that are described from
time to time in the Company’s filings with the Securities and
Exchange Commission, including under Item 1A, “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K and in its
subsequent reports on Forms 10-Q and 8-K. Investors are cautioned
not to place undue reliance on any such forward-looking statements,
which speak only as of the date they are made. Except as required
by law, 23andMe does not undertake any obligation to update or
revise any forward-looking statements whether as a result of new
information, future events, or otherwise.
Investor Relations Contact:
investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Historical Stock Chart
From Mar 2024 to Apr 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From Apr 2023 to Apr 2024